IRWD लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 01:30):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Stats
आज की मात्रा	3.00M
औसत मात्रा	2.74M
बाजार मूल्य	1.04B
EPS	$-0.0264 ( Q1 \| 2024-05-09 )
अगली कमाई की तारीख	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960 (Sector) 42.63 (Industry) 0
ATR14	$0.00900 (0.14%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-06-18	Shepard Jay	Buy	24 311	Class A Common Stock
2024-06-18	Dreyfus Andrew	Buy	24 311	Class A Common Stock
2024-06-18	Duane Jon R	Buy	24 311	Class A Common Stock
2024-06-18	Mchugh Julie	Buy	24 311	Class A Common Stock
2024-06-18	Moukheibir Catherine	Buy	24 311	Class A Common Stock

INSIDER POWER
39.19
Last 100 transactions
Buy: 2 858 392 \| Sell: 1 078 737

सहसंबंध (AI algo v.1.1b): Undervalued: 0.03% $6.52 paired level. (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

मात्रा सहसंबंध

लंबा: 0.67 (moderate)

छोटा: 0.50 (neutral)

Signal:(59.683) Neutral

Ironwood Pharmaceuticals सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
NERV	0.95
LUNG	0.948
SMSI	0.927
ANIX	0.903
WKME	0.902
MODV	0.9
ELTK	0.899
RAPT	0.899
DBX	0.898
EEIQ	0.896

10 सबसे अधिक नकारात्मक सहसंबंध
BZFD	-0.957
IINN	-0.92
SSIC	-0.919
ACVA	-0.916
MRVI	-0.914
IPKW	-0.909
PPC	-0.907
PUBM	-0.905
HOOD	-0.904
ROOT	-0.898

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Ironwood Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र

-0.30
( neutral )

-0.26
( neutral )

0.00
( neutral )

0.34
( neutral )

0.00
( neutral )

0.24
( neutral )

Ironwood Pharmaceuticals वित्तीय

Annual	2023
राजस्व:	$442.74M
सकल लाभ:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2023
राजस्व:	$442.74M
सकल लाभ:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2022
राजस्व:	$410.60M
सकल लाभ:	$409.18M (99.65 %)
EPS:	$1.130

FY	2021
राजस्व:	$413.75M
सकल लाभ:	$413.75M (100.00 %)
EPS:	$3.26

Financial Reports:

No articles found.

Ironwood Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.